Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- 80%-Plus Doctors Seek In-Person Meetings with Reps: Lilly Survey
April 16, 2024
- Meiji Reaffirms 2028 Launch Plan for New Vaccine Site as METI Grants Finalized
April 16, 2024
- Nxera Grants Pivlaz’s Korean Commercial Rights to Handok
April 16, 2024
- Vabysmo Set for 2025 Filing for Angioid Streaks after Japan Trial Success
April 16, 2024
- Xofluza Approved for Pediatric Use in Taiwan: Shionogi
April 16, 2024
- Fujifilm to Invest 180 Billion Yen to Bolster Biologic CDMO Biz in North America
April 15, 2024
- Astellas Slashes FY2023 Profit Forecasts on Gene Therapy Impairment Loss
April 15, 2024
- Takeda Files 2-Dose Vial Version of Novavax COVID Vaccine
April 15, 2024
- MSD Files Keytruda Plus Chemo for Endometrial Cancer in Japan
April 15, 2024
- Wholesaler Purchase Prices of Unprofitable Drugs on Upward Trend after FY2024 Revision
April 12, 2024
- Japan Autoimmune Drug Market Likely to Top 1 Trillion Yen in 2033: Fuji Keizai
April 12, 2024
- Smallpox Drug TPOXX Filed in Japan after Govt Request
April 12, 2024
- Moderna, Tohoku Biobank Start Epidemiology Study on Latent Viruses
April 12, 2024
- ASKA’s Birth Control Pill Makes Mark in Japan PIII Study
April 12, 2024
- Moderna Plots Successive Launches in Japan, Updated COVID Jab by Fall: Medical Chief
April 11, 2024
- GSK, Nagasaki University Begin Large-Scale Epidemiological Study on RSV
April 11, 2024
- Teijin Out-Licenses Narcolepsy Drug to France’s Bioprojet
April 11, 2024
- AZ/Fujifilm Develop Chemoradiotherapy Database for Lung Cancer
April 10, 2024
- Hypertension Therapy App Might Reduce Use of Antihypertensives: CureApp
April 10, 2024
- Otsuka/Lundbeck Seek PTSD Nod for Rexulti in US
April 10, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…